Matches 1 - 50 out of 315 1 2 3 4 5 6 7 >


Match Document Document Title
US20050181971 Treatment of type i diabetes mellitus  
Use of a growth hormone antagonist to reduce the overnight insulin requirement of a patient suffering from Type I diabetes mellitus or from dawn phenomenon.
US20110230404 Glycoproteins Produced in Plants and Methods of Their Use  
Methods of increasing the yield in plant expression of recombinant proteins comprising engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive...
US20120129766 METHODS OF TREATING FGF21-ASSOCIATED DISORDERS  
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods...
US20130150293 METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN  
The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.
US20110256130 METHODS OF TREATING INFLAMMATORY DISORDERS  
Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of...
US20140107022 CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20140094406 CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20130331317 CHIMERIC FIBROBLAST GROWTH FACTOR 19 PROTEINS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20130331316 CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20110263495 METHODS AND KITS FOR TREATING DISEASE BY ADMINISTERING INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-2  
The present invention is directed to methods of treating Type I diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present...
US20100322894 Combination Therapies for Treating Type 1 Diabetes  
In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.
US20140155316 FIBROBLAST GROWTH FACTOR 1 PROTEIN FRAGMENTS AND METHODS OF USE  
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and...
US20110070237 METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM  
Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in...
US20110002994 METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT  
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to...
US20110190730 METHODS OF INDUCING PLURIPOTENCY INVOLVING OCT4 PROTEIN  
The invention relates to a method of inducing pluripotency in a responsive mammalian cell, which comprises introducing into the cell an effective amount for initiating pluripotency within the cell...
US20140057832 USE OF RELAXIN TO INCREASE ARTERIAL COMPLIANCE  
The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present...
US20110286997 Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes  
Compositions and methods for the detection and treatment of T1D are provided.
US20110236370 Genetic Alterations on Chromosomes 21q, 6q and 15q and Methods of Use Thereof for the Diagnosis and Treatment of Type I Diabetes  
Compositions and methods for the detection and treatment of T1D are provided.
US20120046224 TREATMENT OF DIABETES AND METABOLIC SYNDROME  
Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating...
US20110190729 METHODS OF INDUCING PLURIPOTENCY INVOLVING SOX2 PROTEIN  
The invention relates to a method of inducing pluripotency in a responsive mammalian cell, which comprises introducing into the cell an effective amount for initiating pluripotency within the cell...
US20140243260 CHIMERIC FIBROBLAST GROWTH FACTOR 23 PROTEINS AND METHODS OF USE  
The present invention relates to an isolated chimeric protein. The isolated chimeric protein includes an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion...
US20070172453 Tolerogenic approach for type 1 diabetes  
The present invention provides compositions and methods for the treatment and prevention of type I diabetes.
US20120232004 Methods for Treating Autoimmune Disorders, and Reagents Related Thereto  
The invention generally relates to improved methods for the treatment or prophylaxis in animal subjects (including humans) of autoimmune disorders including Type I diabetes, septic shock, multiple...
US20110262386 METHODS OF TREATING INFLAMMATION  
Disclosed herein, in certain embodiments, is a method for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an active agent that inhibits (i) MIF binding...
US20140221277 Method For Elevating Prolactin In Mammals  
Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also...
US20130012431 Method For Elevating Prolactin In Mammals  
Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also...
US20130130975 Methods of Treating Glucose Metabolism Disorders  
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided.
US20150023984 Genetic Alterations Associated with Type I Diabetes and Methods of Use Thereof for Diagnosis and Treatment  
Compositions and methods for the detection and treatment of T1D are provided.
US20110243922 Genetic Alterations Associated with Type I Diabetes and Methods of Use Thereof for Diagnosis and Treatment  
Compositions and methods for the detection and treatment of T1D are provided.
US20120258094 METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE CTLA4 MOLECULE  
The present invention relates to compositions and methods for treating autoimmune diseases, such as diabetes, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from...
US20140093519 METHODS FOR PANCREATIC TISSUE REGENERATION  
Disclosed are methods of expanding populations of pancreatic cells or inducing the generation of pancreatic progenitor cells in a subject or in culture using a therapeutically effective amount of...
US20140037634 REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF  
The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A...
US20130231277 CHIMERIC FGF21 PROTEINS WITH ENHANCED BINDING AFFINITY FOR BETA-KLOTHO FOR THE TREATMENT OF TYPE II DIABETES, OBESITY, AND RELATED METABOLIC DISORDERS  
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”)...
US20140213512 Method of Treating or Ameliorating Type 1 Diabetes Using FGF21  
Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia,...
US20120277147 PREVENTION OF HYPOGLYCAEMIA IN DIABETES MELLITUS TYPE 2 PATIENTS  
A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36Exendin-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, and (b) a...
US20130035280 Method and means for identifying substances which inhibit IgE production  
The invention relates to the field of biomedical and pharmacological research, in particular to the area of immunology, allergies and autoimmune diseases. The inventors have shown that SWAP-70 is...
US20110104156 Methods and materials for treating autoimmune and/or complement mediated diseases and conditions  
Disclosed are methods for treating an autoimmune and/or complement mediated disease or condition in a subject. The methods include administering to the subject a compound which inhibits the...
US20150111821 MUTATED FIBROBLAST GROWTH FACTOR (FGF) 1 AND METHODS OF USE  
The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such...
US20060008829 Multimarker panel based on PIGF for diabetes type 1 and 2  
The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention...
US20150164986 METHOD OF TREATING TYPE I DIABETES USING APOLIPOPROTEIN AIV  
Methods for treating type one diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type one diabetes mellitus are disclosed, including combination...
US20140328794 ALBUMIN FUSION PROTEINS  
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors...
US20140086903 CD37 IMMUNOTHERAPEUTIC AND COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC THEREOF  
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as...
US20080175921 Colloidal formulation of long-acting insulin and its preparation  
The invention relates to injectable long-acting insulin formulations for the treatment of type I and II diabetes in humans and animals. The main objective of the invention is to provide a...
US20140286906 USE OF IGF-1 IN THE MODULATION OF TREG CELL ACTIVITY AND THE TREATMENT AND PREVENTION OF AUTOIMMUNE DISORDERS OR DISEASES  
The present invention relates to the use of the Insulin-like growth factor-I (IGF-1) in immune modulation and/or in the treatment or prevention of pathogenic or aberrant immune responses or...
US20120214729 COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION  
The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits...
US20140057838 OSTEOBLAST-EXPRESSED LIPOCALIN 2 REGULATES GLUCOSE METABOLISM  
Diseases including diabetes, metabolic syndrome, and obesity or obesity-related diseases are due to impairment in glucose metabolism. The skeleton has been shown to regulate energy metabolism and...
US20150010508 Methods And Compositions Relating To Islet Cell Neogenesis  
The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating...
US20150099697 METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP)  
Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the...
US20110046055 THERAPEUTIC AGENT FOR DIABETES  
Disclosed are method for treating diabetes, a protein for treatment of diabetes, and pharmaceutical composition comprising the same. The protein is human mature chemerin, which can be used to...
US20060239934 SUPERIOR CONTROL OF BLOOD GLUCOSE IN DIABETES TREATMENT  
Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose...

Matches 1 - 50 out of 315 1 2 3 4 5 6 7 >